Scolr's ANDA for CDT-Based Pseudoephedrine Accepted for Review By FDA
Posted on: Monday, 29 September 2008, 12:00 CDT
Scolr Pharma, a specialty pharmaceutical company, has announced that the FDA has accepted for review the company's abbreviated new drug application for a 120mg 12-hour pseudoephedrine tablet based on its patented controlled delivery technology platform.
The abbreviated new drug application (ANDA) was submitted to the FDA on August 5, 2008. This is said to be the first application filed by Scolr Pharma with the FDA.
Pseudoephedrine is a decongestant that is an active ingredient in Allegra D, Sudafed PSE, Claritin D, Zyrtec D and other over-the-counter and prescription products.
Tanya Raco, associate vice president of regulatory affairs and quality assurance at Scolr Pharma, said: "We believe the timely notification received from the FDA is a testimony to the quality of our filing. If approved by the FDA, our pseudoephedrine formulation could provide important competitive advantages over existing marketed formulations in terms of both tablet size and manufacturing costs."
Source: Datamonitor
Related Articles
- FDA Accepts Tris Pharma's ANDA with Paragraph IV Certification for a Generic Equivalent to Delsym
- SCOLR Pharma's ANDA for 12-Hour CDT-Based Pseudoephedrine Accepted for Review By U.S. FDA
- FDA Approves Sun Pharma's Benzonatate Capsules
- FDA Approves Sun Pharma's Fosphenytoin Sodium Injection
- Kiadis Pharma Obtains FDA Approval to Start a Phase III Clinical Trial for Reviroc(TM) in the United States
- Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
- FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
- FDA Approves SCHWARZ PHARMA's Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease in USA
- FDA Says MGI Pharma Brain Tumor Ad Misleading
 |
 |
User Comments (0)
RSS Feeds